Pharmacological interventions for peripheral artery disease.

Area of Science:

• Vascular Medicine
• Cardiovascular Disease
• Pharmacology

Background:

• Peripheral arterial disease (PAD) involves atherosclerosis and thromboembolism affecting major arteries.
• PAD significantly increases cardiovascular morbidity and mortality risks.
• Therapeutic goals include risk reduction, enhanced walking capacity, and prevention of critical limb ischemia.

Purpose of the Study:

• To review current pharmacological and non-pharmacological therapies for PAD.
• To highlight the importance of exercise, smoking cessation, and antiplatelet therapy.
• To emphasize the need for rigorous clinical trial designs for future PAD drug development.

Main Methods:

• Review of existing literature on PAD treatments.
• Analysis of the efficacy of antiplatelet, anticoagulant, and other pharmacological agents.
• Evaluation of the role of exercise and smoking cessation in PAD management.

Main Results:

• Antiplatelet therapy (aspirin) is a cornerstone for PAD patients without contraindications.
• Combination therapy or anticoagulants have not demonstrated additional benefits.
• Many studied drugs offer limited or potential benefits for symptom relief and functional improvement.

Conclusions:

• Current PAD management prioritizes cardiovascular risk reduction and symptom improvement.
• Future drug development requires stringent protocols to assess efficacy in claudication, disease progression, and mortality.
• Novel therapies should target endothelial function, vascular repair, and collateral circulation enhancement.